Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy

BACKGROUND: Cabozantinib is a tyrosine kinase inhibitor with activity against vascular endothelial growth factor receptor 2 (VEGFR2) and MET that has demonstrated clinical activity in advanced solid tumors. This open-label, phase II trial evaluated cabozantinib in patients with recurrent or refracto...

Descripción completa

Detalles Bibliográficos
Autores principales: Wen, Patrick Y, Drappatz, Jan, de Groot, John, Prados, Michael D, Reardon, David A, Schiff, David, Chamberlain, Marc, Mikkelsen, Tom, Desjardins, Annick, Holland, Jaymes, Ping, Jerry, Weitzman, Ron, Cloughesy, Timothy F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777496/
https://www.ncbi.nlm.nih.gov/pubmed/29016998
http://dx.doi.org/10.1093/neuonc/nox154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5777496/
https://www.ncbi.nlm.nih.gov/pubmed/29016998
http://dx.doi.org/10.1093/neuonc/nox154

Ejemplares similares